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Summary The role of post-operative radiotherapy for patients with non-small-cell lung cancer (NSCLC) is
unclear despite five previous randomised trials. One deficiency with these trials was that they did not include
adequate TNM staging, and so the present randomised trial was designed to compare surgery alone (S) with
surgery plus post-operative radiotherapy (SR) in patients with pathologically staged TI-2, NI-2, MO
NSCLC. Between July 1986 and October 1993, 308 patients (154 S, 154 SR) were entered from 16 centres in
the UK. The median age of the patients was 62 years, 74% were male, >85% had normal or near normal
levels of general condition, activity and breathlessness, 68% had squamous carcinoma, 52% had had a
pneumonectomy, 63% had NI disease and 37% N2 disease. SR patients received 40 Gy in 15 fractions starting
4-6 weeks post-operatively. Overall there was no advantage to either group in terms of survival, although
definite local recurrence and bony metastases appeared less frequently and later in the SR group. In a subgroup
analysis, in the NI group no differences between the treatment groups were seen, but in the N2 group SR
patients appeared to gain a one month survival advantage, delayed time to local recurrence and time to
appearance of the bone metastases. There is, therefore, no clear indication for post-operative radiotherapy in
Nl disease, but the question remains unresolved in N2 disease.
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For patients with potentially resectable, non-small-cell lung
cancer (NSCLC) without distant metastases, the standard
treatment is an intended curative resection. In 1986, at the
time this trial was planned and activated, a number of studies
had already clarified some of the factors affecting resectability
and subsequent prognosis.
Firstly, it was already clear that the duration of
subsequent survival was greatly reduced if the mediastinal
nodes were found to be involved. For example, in a
consecutive series of 245 patients undergoing curative
resection, Wilkins et al. (1978) reported 5-year survival rates
of 42% in patients without mediastinal node involvement
compared with only 16% with such involvement. Greschuch-
na and Maassen (1980) reported corresponding rates of 37%
and 11%, and broadly similar results were reported by others
(Edwards, 1979; Mountain, 1986).
Secondly, the importance ofcareful preoperative staging in
the selection of patients suitable for intended resection was
appreciated, particularly the need to avoid inappropriate
thoracotomy in patients with T3 tumours, gross mediastinal
node involvement or metastatic disease (Pearson, 1980; Spiro
and Goldstraw, 1984). This need can only be met if, in
patients otherwise suitable for thoracotomy, the mediastinum
is staged, using such techniques as computerised tomography
(CT), cervical mediastinoscopy and anterior mediastinotomy
(if so indicated for left upper lobe tumours), and if clinical
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and laboratory indications of possible metastatic disease are
adequately investigated (Matthews et al., 1973; Goldstraw et
al., 1983; Spiro and Goldstraw, 1984).
Finally, in patients found to have resectable, potentially
curable disease at thoracotomy, prognosis was known to be
affected by whether the mediastinal nodes are found, at that
stage, to be macroscopically or microscopically involved and,
by which particular nodal groups are affected, emphasising
the need, in assessing prognosis, for careful nodal mapping at
thoracotomy (Naruke et al., 1978; American Thoracic
Society, 1983). Mediastinal nodes need to be sampled and
labelled from the lung hilum, the main carinal group, and one
other adjacent station, and their microscopical involvement
reported separately.
In the light of the above observations, the question arises
whether, among patients adequately assessed for resection,
post-operative radiotherapy prolongs survival in those with,
and in those without, mediastinal node involvement (Perez,
1982). A number of retrospective surveys claimed to show
that it was of benefit to patients with mediastinal node
metastases (Green et al., 1975; Kirsh et al., 1976; Choi et al.,
1980; Chung et al., 1982; Newman et al., 1983); but these
surveys were in general small and involved unreliable
comparsions against either historical controls or other series
from different centres.
Results from five randomised trials, however, were
inconclusive and inconsistent. Paterson and Russell (1962),
in a trial of 202 patients randomised to pneumonectomy with
or without post-operative mediastinal orthovoltage radio-
therapy, showed no difference in survival, the 3-year survival
rates being 36% in the no radiotherapy group and 33% in
the radiotherapy group. However, the trial included 43
patients with poorly differentiated anaplastic or oat cell
carcinoma, no TNM staging was done either before or during
surgery, and the intake was stratified only by operatingsurgeon and patient's age; the influence on the result of
histology, mediastinal node involvement and other variables
of possible prognostic importance is uncertain. A study by
Bangma (1971) is often mentioned in this context, but it was
not a randomised trial; the patients were assigned alterna-
tively to the two treatment groups. Even so, in this small
study (73 patients) also, no benefit was shown for post-
operative radiotherapy.
In an analysis involving 175 of 224 randomised patients
with tumour confined to the lung, that is, with no intra-
operative evidence of lymph node metastases (Van Houtte et
al., 1980), survival was better in the non-irradiated group, the
5-year survival rate being 43% in this group compared with
24% in the irradiated group. Although the survival difference
was not statistically significant, the size of the effect observed
raised the question whether post-operative mediastinal
radiotherapy might be harmful in patients with NO or NI
disease.
In a trial by the Lung Cancer Study Group (1986), in which
230 patients with resected stage II or III MO, squamous
carcinomas were pathologically staged intra-operatively and in
which the randomisation was stratified by stage, weight loss,
age and institution, there was no evidence that post-operative
radiotherapy improved survival, even in patients with N2
disease, although in this latter group the local recurrence rate
was substantially and significantly lower.
In contrast to the above four trials, in a randomised trial
conducted by the European Organization for Research and
Treatment of Cancer, 230 of 392 patients with squamous
carcinoma were evaluated, 88 of whom had regional lymph
node metastases (Israel et al., 1979). The 3-year tumour-free
survival rate was 70% in 104 patients given post-resection
radiotherapy compared with 50% in 126 treated by resection
without post-operative radiotherapy. This result must be
treated with caution because of the large and unbalanced
numbers of patients excluded, and full details have not been
published in a refereed journal.
The present trial was therefore undertaken to make a
randomised comparison of post-operative mediastinal radio-
therapy vs no radiotherapy in patients with NSCLC
pathologically staged as TI-2, NI-2, MO. Although
patients would be randomised after a resection that was
considered complete and potentially curative, they would be
carefully staged to ensure entering only a minimum of those
with unsuspected metastatic disease. The two treatment
policies were to be compared in terms of survival, time to
local recurrence, site and time to occurrence of metastases,
and general condition, performance status and breathlessness.
However, in view of the results, summarised above, of the
other randomised trials, it was considered that the addition of
post-operative radiotherapy might be less effective in patients
with Nl disease compared with those with microscopic N2
disease, or might even be deleterious in patients with NI
disease (Van Houtte et al., 1980). It was therefore planned
that, within this one trial, as well as obtaining an overall
estimate of treatment effect, a subgroup analysis for the two
nodal status groups should be presented.
Materials and methods
Preoperative eligibility criteria
Patients of either sex aged 75 years or less were potentially
eligible for the trial if preoperatively they had normal or near
normal activity (WHO grades 0-2, World Health Organiza-
tion, 1979), even if symptoms were present. They had to have
lung and cardiac function adequate for the proposed
resection, to have received no previous radiotherapy or
chemotherapy and no previous surgery (except diagnostic) for
the current disease, and to have no other concomitant
malignant disease and no other serious condition contra-
indicating surgery or radiotherapy.
Preoperative staging was recommended, using wherever
possible a CT scan of the chest (including mediastinum and
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contralateral lung), upper abdomen (including liver, adrenals
and kidneys) and brain. If the CT chest scan showed
mediastinal abnormalities, cervical mediastinoscopy and (for
left upper lobe tumours) anterior mediastinotomy were
recommended. If CT scans could not be performed,
mediastinoscopy or mediastinotomy were to be done
whenever possible. If there was radiographic or broncho-
scopic evidence of mediastinal lymphadenopathy, CT scan,
mediastinoscopy or mediastinotomy were recommended. If
there was any reason to suspect metastases it was required
that every effort be made to confirm or exclude them by
whatever additional investigations were deemed necessary.
Operative andpost-operative eligibility criteria
Patients had to have NSCLC of any cell type, except
carcinoid tumour, which was pathologically staged as Tl-
2, NI-2, MO. Histological diagnosis and the pathological T
staging, based on the resected specimen, were made by the
local histopathologist. To ensure uniformity of classification,
histology slides were reviewed by a single reference
histopathologist.
Patients must have had an intended curative resection
deemed to have been complete. Patients were ineligible if the
bronchial margins of the resection specimen were invaded by
cancer on local histopathological examination, but those with
the visceral pleura involved were eligible provided the tumour
was not adherent to the parietal pleura and there was no
pleural effusion. Patients should have had no evidence of
residual or metastatic disease during the first 2 weeks post-
operatively.
At operation as many as possible of the ipsilateral lymph
node stations (Naruke et al., 1978) were to be sampled,
including at least two mediastinal stations, the main
subcarinal nodes and (except for lower lobe tumours) the
high paratracheal nodes. For lower lobe tumours, the para-
oesophageal or pulmonary ligament nodes were to be
sampled. The pathological N staging was made by the local
histopathologist.
Treatment allocation
Once the trial had been approved by the local ethics committee
and individual patient consent was obtained, clinicians
telephoned the MRC Cancer Trials Office between 2 and 4
weeks post-operatively to obtain a treatment allocation to
either radiotherapy or no radiotherapy. Patients were
allocated to one of the two regimens using a minimisation
procedure stratifying for surgeon, TNM stage (TlNlMO,
T2NlMO, TlN2MO, T2N2MO or unknown at time of
randomisation) and histology (squamous, adenocarcinoma,
large cell, other or unknown at time of randomisation).
Surgery with no post-operative radiotherapy (S)
Patients in this group received no further specific anti-cancer
treatment unless their disease recurred. Any subsequent
treatment was given at the discretion of the individual
clinician.
Surgery with post-operative radiotherapy (SR)
Patients allocated to immediate post-operative radiotherapy
received a course of radiotherapy to include the bronchial
stump, mediastinal nodes and both lung hila, given in
accordance with local practice, starting 4 to 6 weeks after
the date of operation. If the tumour was in an upper lobe or
if high mediastinal nodes were involved, the field included
both supraclavicular fossae. The upper border of the field
was never lower than the supraclavicular notch and the lower
border extended at least 3 cm below the carina. The central
midline dose was 40 Gy given in daily fractions (f) 5 days a
week over 3 weeks using megavoltage x-ray therapy or 'Co
gamma-ray teletherapy. Parallel opposed fields were to bePost-operative radiotherapy in non-small-cell lung cancer
$0 Medical Research Council Lung Cancer Working Party
634
used with no correction for extra transmission through lung
tissue. The spinal cord dose was limited to 35 Gy by the use
of posterior lead blocks. Because of the greater contribution
from the anterior field at the midplane than at the cord, the
midplane dose was likely to be above 35 Gy.
Reports and investigations
The admission report included details of the staging
procedures, measurement of the blood haemoglobin, white
cell and platelet counts, an assessment of general condition,
WHO performance status and degree of breathlessness
according to the groupings shown in Table II, details of the
operation (extent of resection and lymph node station
numbers sampled), site of tumour, any post-operative
complications experienced and the TNM stage.
Patients in the S group were seen and assessed at 6 and 9
weeks from operation, and those in the SR group at the start
and end of radiotherapy. Both groups were then seen at 4, 6,
9, 12, 18 and 24 months from operation, and annually
thereafter. The follow-up reports included details of the
patient's blood counts, any evidence of recurrence of the
primary cancer, metastases and any anti-cancer treatment.
Clinicians reported the presence of recurrence and metastases
as 'definite' or 'suspected' according to whatever evidence
was available to them. They also reported the patients'
general condition, WHO performance status and degree of
breathlessness.
All patients were followed to death, even if they were
subsequently found not to have satisfied the eligibility criteria
for the trial, or if they did not for any reason receive the
allocated treatment.
Statistical methods
All analyses are based on the intention to treat principle
(Lewis and Machin, 1993). Survival was calculated from the
date of randomisation until death or the date last known to
be alive. The Kaplan-Meier (KM) estimate was used to
calculate survival curves and the Mantel-Cox version of the
log-rank test to make treatment comparisons. Associated
confidence intervals (CIs) for the corresponding hazard ratios
(HRs) were calculated. The same techniques were used to
estimate and compare the time to occurrence of local
recurrence and distant metastases. Patients with no such
reported event were censored at date of death or date last
seen alive.
The trial data were managed using the COMPACT
program (COMPACT Steering Committee, 1991).
The proposed intake of 300 patients was based on the
calculation that 5-year survival rates of 20% (S group) and
36% (SR group) would provide a 90% chance of obtaining a
significant result at the 5% level. It was recognised that these
figures were approximate because of the unpredictable mix of
patients with NI and N2 disease. It was hoped that this
intake would be accrued within 3 years.
Results
Patients in the trial
Between July 1986 and October 1993 308 patients were
admitted from 16 centres in the UK. Exactly half (154) were
allocated to each treatment.
Preoperative characteristics
Table I shows the staging procedures used and the numbers
considered abnormal, suspicious and normal. The majority of
patients had chest radiography (97%) and a bronchoscopy
(95%) and of these 94% and 72%, respectively, were
abnormal. A total of 73% of the patients had a CT chest
scan and 95% of these were considered abnormal. Only a
small proportion of patients had cervical mediastinoscopy
(8%), anterior mediastinoscopy (3%) and mediastinotomy
(2%).
Most patients (229, 74%) also had additional staging
procedures to exlcude the presence of metastases. Table I
shows that 38% of patients had a CT of the upper abdomen
and 39% an abdominal ultrasound (five patients having
both). The other investigations suggested in the protocol were
very rarely used. Using these additional staging procedures,
abnormalities were observed in five patients (3S, 2SR), but
none of these were considered to be caused by metastases.
Nearly all the patients (Table II) had normal or near
normal categories (grades 0 or 1) of general condition (90%),
performance status (97%) and breathlessness (85%). The
majority were male (74%), and at operation the median age
was 62 years (range 37-77 years). No patients had an
abnormally low (<3000 mm-3) white blood cell count or low
platelet count (< 100000 mm-3), but six patients (2S, 4SR)
had a haemoglobin of < 10.0 g dl-1 and three (2S, 1SR) a
high white cell count of >20000 mm
Operative and post-operative characteristics
Fifty-two per cent of the patients (Table III) had had a
pneumonectomy (48% of the patients with NI disease, 58%
of those with N2) and 45% a lobectomy (48% of those with
NI, 41% of those with N2). The majority had squamous
carcinoma (68%) and the site of disease was left upper lobe
in 36%, right upper lobe in 22%, left lower lobe in 15% and
right lower lobe in 13%.
The median number of node groups sampled was three
(range 0-9), and of these a median of one was found to be
involved. The majority (85%) of patients in whom the hilar
nodes were the most central group involved were classified as
having NI disease.
Table I Preoperative staging procedures
S SR Total
Staging procedures No. (%) No. (%) No. (%)
To confirm diseasea
Chest radiography
Abnormal 143 (95) 136 (92) 279 (94)
Suspicious 5 (3) 9 (6) 14 (5)
Normal 2 (1) 3 (2) 5 (2)
NA/ not done 4 6 10
Bronchoscopy
Abnormal 105 (72) 108 (72) 213 (72)
Suspicious 8 (6) 14 (9) 22 (7)
Normal 32 (22) 27 (18) 59 (20)
NA/ not done 9 5 14
CT scan of chest
Abnormal 113 (97) 101 (93) 214 (95)
Suspicious 3 (3) 7 (6) 10 (4)
Normal 0 (0) 1 (1) 1 (0)
NA/ not done 38 45 83
To exclude distant metastasesb
CT upper abdomen
Normal 64 (100) 50 (93) 114 (97)
Suspicious 0 (0) 3 (6) 3 (3)
Normal 0 (0) 1 (2) 1 (1)
NA/ not done 90 100 190
Abdominal ultrasound
Abnormal 54 (100) 64 (97) 118 (98)
Suspicious 0 (0) 1 (2) 1 (1)
Abnormal 0 (0) 1 (2) 1 (1)
NA/ not done 100 88 188
Total patients 154 154 308
a24 patients had cervical mediastinoscopy, 10 anterior mediastino-
scopy, 5 mediastinotomy and 0 gallium chest scan. b5 patients had a
CT brain scan (1 S abnormal), 2 a laparoscopy, 3 bone radiology (1 S
abnormal), 36 radioisotope bone scan (1 S abnormal) and 1 a marrow
trephine.Post-operative radiotherapy in non-small-cell lung cancer
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As reported over the telephone at the time of randomisa-
tion, 47% of the patients had T2NlMO disease, 29%
T2N2MO, 16% TINIMO and only 8% TIN2MO.
The median time from operation to randomisation was 15
days (range 3-167 days), 133 (43%) being earlier and 41
(13%) later than the protocol recommendation of 14-28
days.
The distributions of all the above characteristic between
the two regimens were very similar.
Ineligible patients
Seventeen patients (lOS, 7SR) did not fit the exact eligibility
criteria as laid down in the protocol: two (both S) had no
evidence of lymph node involvement, two (both SR) had
bronchial margins involved, one (S) had lung metastases, one
(SR) had had previous radiotherapy for breast cancer, four
(2S, 2SR) were aged >75 years and seven (5S, 2SR) were
randomised more than 8 weeks after their operation.
However, all 17 patients have been included in all the
following analyses which are based on the intention to treat
principle. An analysis excluding these patients made no
material difference to the conclusions.
Protocol treatment received
Of the 154 SR patients, 15 (10%) did not start radiotherapy
and 3 (2%) did not complete their allocated course. Of the 15
who did not start this was because of refusal in four patients,
death in three, severe illness in three, administrative error in
one, previous radiotherapy for breast cancer in one and
refusal by the radiotherapist to give the protocol regimen in
one. For the remaining two, no reason was given. Of the
three patients who did not complete their full course (40 Gy/
15 f): one refused after 5 f, one stopped after 12 f because of
brain metastases and one stopped after 13 f because of severe
oesophagitis.
Of the 136 patients who did receive their allocated course
of post-operative radiotherapy, 55 (36% of the 154 patients
allocated) had radiotherapy given exactly as specified in the
protocol, and 21 patients (14%) had minor deviations,
Table II Preoperative characteristics
S SR Total
Characterisitc No. (%) No. (%) No. (o)
Sex
Male 117 (76) 112 (73) 229 (74)
Female 37 (24) 42 (27) 79 (26)
Age
<45 5 (3) 2 (1) 7 (2)
45-54 18 (12) 26 (17) 44 (14)
55-64 70 (45) 70 (45) 140 (45)
65 -74 58 (38) 53 (34) 111 (36)
75+ 3 (2) 3 (2) 6 (2)
General condition
0 Excellent 35 (23) 38 (25) 73 (24)
1 Good 104 (68) 99 (65) 203 (66)
2 Fair 14 (9) 16 (10) 30 (10)
NA 1 1 2
WHO performance status
0 Normal 64 (44) 71 (48) 135 (46)
1 Activity restricted 77 (53) 70 (48) 147 (50)
2 Up>50% waking time 4 (3) 6 (4) 10 (3)
NA 9 7 16
Breathlessness
0 No dyspnoea 61 (41) 63 (42) 124 (42)
1 Walks on flat 65 (44) 64 (42) 129 (43)
2 Walks over 100 yards 21 (14) 24 (16) 45 (15)
NA 7 3 10
Total patients 154 154 308
defined as being within 10% of the protocol specification.
A further 57 patients (37%) had the correct treatment, or
within 10% of it (in terms of dose and fractions), but
deviated from the protocol in the timing, field size or number
of fields. Of the remaining three patients (2%), two received
40 Gy in 20 f and one received 32 Gy in 8 f.
Adverse effects
Post-operative complications In these patients, who all had
to have survived a successful resection for a minimum of 2
weeks post-surgery to be eligible for the trial, few post-
operative complications were reported: 14 patients had mild
and 7 moderate lung infections, three mild and one moderate
wound infections, and one mild and one moderate pleural
infections. In addition, 32 patients had some other minor
complications.
Reactions to allocated radiotherapy In contrast however a
large proportion, 96 (69%) of the 139 patients who were
allocated to and started radiotherapy were reported as having
some adverse reactions to it. The main reactions mentioned
were oesophagitis, dysphagia, nausea, vomiting, sore throat
and lethargy. In 36 patients, symptoms were considered mild,
in 45 moderate and in 15 severe.
Further treatment
The numbers of patients requiring further surgery or
treatment with chemotherapy or radical radiotherapy at any
time were very similar in the two regimens. Ten patients in
the S group had further surgery as did ten in the SR group,
ten and five patients, respectively, received chemotherapy,
and three S patients had radical thoracic radiotherapy.
However, 44 (29%) patients in the S group received
Table III Operative and post-operative characteristics
S SR Total
Characterisitc No. (o) No. (G) No. (%)
Operation
Pneumonectomy 75 (49) 84 (55) 159 (52)
Lobectomy 76 (49) 64 (42) 140 (45)
Segmentectomy 3 (2) 4 (3) 7 (2)
Sleeve resection 0 (0) 2 (1) 2 (1)
Histologya
Squamous 101 (67) 101 (68) 202 (68)
Adenocarcinoma 36 (24) 36 (24) 72 (24)
Large cell 10 (7) 8 (5) 18 (6)
Other 3 (2) 4 (3) 7 (2)
Not reported 4 5 9
Site
Left
Upper Lobe 55 (36) 55 (36) 110 (36)
Hilum 7 (5) 9 (6) 16 (5)
Lower Lobe 24 (16) 21 (14) 45 (15)
Indeterminate 0 (0) 1 (1) 1 (0)
Right
Upper Lobe 38 (25) 30 (19) 68 (22)
Hilum 2 (1) 7 (5) 9 (3)
Middle Lobe 5 (3) 10 (6) 15 (5)
Lower Lobe 21 (14) 20 (13) 41 (13)
Indeterminate 1 (1) 1 (1) 2 (1)
Not reported 1 0 1
TNM stagea
Ti Ni MO 23 (16) 23 (16) 46 (16)
T2 Ni MO 68 (47) 69 (48) 137 (47)
TI N2 MO 13 (9) 10 (7) 23 (8)
T2 N2 MO 41 (28) 42 (29) 83 (29)
Not reported 9 10 19
Total patients 154 154 308
aStratification factor.Post-operative radiotherapy in non-small-cell lung cancer
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palliative radiotherapy compared with 28 (18%) in the SR
group. Most of this (74%) was for metastases.
Survival
Of the 308 patients, 221 (72%) have died, and the median
follow-up of the 87 surviving patients is 30 months, range 7
months to 7 years. Figure 1 shows the KM plots by
treatment regimen. Although initially there appears to be a
slight advantage to the S group, and the median survival
times are 19 months for the S group and 17.5 months for the
SR group, the curves cross at approximately 20 months and
the HR is 1.00 (95% CI 0.77-1.30, P=0.99).
Local recurrence
Local recurrence was reported by the clinicians as none,
suspected or definite. A total of 72 (23%) patients (45S,
27SR) were reported as having definite, and a further 59
(19%) patients (28S, 31SR) as having suspected local
recurrence at some time in their lives. The time to the first
reporting of recurrence (either suspected or definite) was
plotted using KM curves, patients who died without local
recurrence being censored at the date of death. The log-rank
plots are shown in Figure 2. There was no clear evidence that
SR was better than S (HR 1.23, 95% CI 0.87- 1.73, P=0.24).
However, an analysis of the time to definite local recurrence
indicated an advantage to the SR regimen (HR 1.64, 95% CI
1.03-2.61, P=0.04).
Distant metastases
Table IV shows the number of patients in whom distant
metastases were suspected or confirmed. The patterns of
failure were very similar for the two regimens. Overall,
distant metastases developed in 67% of the S group
compared with 51% of the SR group, and the major sites
were bone and brain. The log-rank test was used to check if
there were differences in the time to occurrence. The upper
section of Figure 3 shows the KM plots for the appearance of
any metastases. Although the curves diverge at approximately
1 year, there was no overall difference (HR 1.28, 95% CI
0.95-1.71, P=0.10). The only specific site in which a
significant difference was observed was bone (lower section
of Figure 3), and in the S group bony metastases were more
common and developed earlier (HR 2.09, 95% CI 1.35-3.22,
P=0.001). Analyses using only confirmed metastases gave
very similar results.
Changes in general condition, performance status and
breathlessness
Comparing the percentages of patients with impaired (grade
2, 3 or 4) general condition, performance status and
breathlessness at each of the nine assessments up to 2 years
showed, for all three variables, that patients allocated to SR
had a period of worse condition during and just after their
radiotherapy (month 1), but thereafter no differences between
the two regimens were observed (data not shown).
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Subgroup analysis of the NJ and N2 groups
The TNM stage was reported over the telephone before
randomisation, 183 patients being considered to have NI
disease (91 being allocated to the S group, 92 to the SR
group), 106 N2 disease (54S, 52SR) and 19 unknown (Table
III). The TNM stage was also recorded on the admission
form but these data have not been used to replace or update
the information, as the numbers of changes and the pattern
of staging of those patients previously unknown, were
different between the two treatment regimens. The following
analyses are therefore based on 289 patients whose nodal
status data were obtained prerandomisation (183 NI, 106
N2). However, repeat analyses using TNM stage from the
admission form gave similar results.
Survival In the NI group 126 (69%) patients have died (60
S, 66 SR) and the KM plot (upper section of Figure 4)
suggests a slight advantage to the S group: the median
survival was 20.5 months in the S group compared with 16.3
months in the SR group, and the proportions of patients
surviving at 1 year were 71% and 60% respectively.
However, by 2 years the curves had come together and
there was no significant difference between the regimens (HR
0.82, 95% CI 0.58-1.16, P=0.26).
In the N2 group 43 (80%) of the S patients and 36 (69%)
of the SR patients have died. The KM plot (lower section of
Table IV Occurrence of suspected or confirmed distant metastases
S SR Log-rank
Metastases No. (%) No. (%) P-value
Any 103 (67) 79 (51) 0.10
Liver 12 (8) 15 (10) 0.48
Brain 27 (18) 28 (18) 0.81
Bone 55 (36) 27 (18) 0.001
Opposite lung 21 (14) 14 (9) 0.26
Nodes 18 (12) 17 (11) 0.97
Others 19 (12) 12 (8) 0.35
Total patients 154 154
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Figure 3 Estimated percentage of patients with (a) no distant
metastases and (b) no bony metastases.
Figure 4) shows an advantage to the SR group (HR 1.35,
95% CI 0.87-2.10, P=0.18). The median survival periods
were 16.2 months in the S group and 17.6 months in the SR
group. The survival curves diverged at about 1 year, thus the
proportions alive at 1 year were similar (S 63%, SR 65%),
but 33% and 43% at 2 years and 21% and 36% at 3 years
respectively.
Local recurrence In the Ni patients, 82 (44%) of the 183
were reported as having either a suspected or definite local
recurrence (45S, 37SR). The log-rank test comparing time to
relapse showed no difference between the regimens (HR 0.99,
95% CI 0.64- 1.53, P=0.96). In contrast, in the N2 patients,
22 (41%) of the S patients were reported as having recurrence
compared with 15 (29%) of the SR patients (HR 1.81, CI
0.95-3.46, P=0.07).
Distant metastases In the NI group the results were, in
general, similar for the two regimens, 58 (64%) of the S
group and 49 (53%) of the SR group having metastases
reported. The commonest sites in both treatment groups were
bone and brain. However, bone metastases were more
common in the S patients (35%) than in the SR patients
(21%), and the KM plot comparing the time to appearance
of bony metastases is shown in the upper section of Figure 5
(HR 1.54, 95% CI 0.89-2.67, P=0.13).
In the N2 group, 38 (70%) ofthe S patients had metastases
compared with 24 (46%) of the SR patients (HR 1.73, 95%
CI 1.05-2.84, P =0.03). The commonest sites were again
bone and brain. Metastases in bone were significantly more
common in the S group than in the SR group and took less
time to develop (HR 3.19, 95% CI 1.53 -6.62, P=0.003). The
KM plots for the appearance ofbony metastases are shown in
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the lower section of Figure 5. In neither group was an
association seen between the appearance of bone metastases
and local recurrence.
Discussion
Local recurrence following surgery with curative intent has
remained a significant problem in the management of
operable NSCLC. In past years, in the absence of effective
chemotherapy for NSCLC, methods of improving local
results have centred on improved surgical techniques and
adjunctive radiotherapy which has usually been given post-
operatively. The five previous randomised trials of post-
operative radiotherapy have not helped in a clear assessment
of its role. This has been due to a variety of factors in their
study design. Of particular importance is the definition of the
various subgroups and in particular those patients at highest
risk of local recurrence, that is with extensive nodal disease
(N2). This present trial was designed so that the question of
post-operative radiotherapy could be addressed with patients
classified on the basis of modern surgical staging methods.
This trial was closed after the target of 300 patients had been
admitted. Further accrual was deemed unlikely because of
increasing interest in adjuvant or neo-adjuvant chemotherapy
as an alternative to the radiotherapy (Holmes, 1994;
Ginsberg, 1994a, b; Rosell et al., 1994a; Non-small Cell
Lung Cancer Collaborative Group, 1995). The definitive
results of three more recent randomised trials in patients with
N, 2 disease (Ricci et al., 1991; Mei et al., 1994; Debevec et
al., 1995) are awaited.
The overall results of the present trial confirm previous
studies in that there was no advantage to survival in the SR
group over that of surgery alone. The non-significant trend
towards improved survival in the N2 group is matched by a
similar trend of reduced local recurrence in this subgroup.
However, a total of only 106 N2 cases makes such subgroup
analysis unlikely to demonstrate modest but clinically
important differences. A meta-analysis to include this present
trial with other published and unpublished randomised trials
is in progress and particular attention will be paid to the
nodal status of patients.
The most striking difference between the two treatment
policies was in the incidence of distant metastases. While the
results for the NI group were generally similar, the incidence
of bone metastases was higher in the S group. In the N2
patients there was a highly significant excess of bone
metastases in the S group. The appearance of bone
metastases occurred steadily over the 3-4 years following
treatment. Moreover, this large excess of bony mestatases
was not simply the result of a relative failure to control local
disease in the S group; there was, in fact, no evidence of an
association between local recurrence and bony metatases.
There was a modest increase in side-effects following the
post-operative radiotherapy over those recorded for the S
group. However, these were not of sufficient magnitude to be
regarded as a contraindication to the treatment.
In conclusion, this trial has provided no convincing
evidence that post-operative radiotherapy affects survival,
local recurrence or the development of metastases in patients
with pathologically staged NI disease. In patients with N2
disease, it substantially reduced metastases and probably
local recurrence. It will be important to determine in longer
term follow-up whether this latter finding is confirmed and
whether radiotherapy also led to a small improvement in
survival. The radiotherapy dose and techniques, although
standard at the time the trial was opened, would not now be
regarded as ideal, because some midline mediastinal nodes
would receive a lower dose as a result of the posterior spinal
cord shielding; the dose to a 1-2 cm midline strip would be
reduced to about 38-39 Gy at the midplane, where most of
the mediastinal nodes lie. However, following surgery there is
usually a shift of the mediastinum towards the treated side
and so the effect of a midline shield may be of little
importance. It is arguable that larger doses given by modern
techniques could have had greater effect. It is important that
in future the role of radiotherapy in preoperative schedules
involving chemotherapy be determined (Holmes and Ruck-
deschel, 1993; Rosell et al., 1994b).
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